InMed Pharmaceuticals issued the following announcement on March 2.

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE:IN; OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to list its common shares ("Common Shares") on the TSX. Final approval of the listing on the TSX remains subject to InMed fulfilling certain customary listing conditions of the TSX on or before the TSX-imposed deadline of May 29, 2018. The Company expects that it will satisfy such conditions in advance of the TSX-imposed deadline. Upon listing on the TSX, the Common Shares will continue to trade under the symbol 'IN'.

"Graduating to the TSX is a significant accomplishment for InMed," said Eric A. Adams, CEO & President. "This milestone furthers our corporate goal of securing a leadership position in this high-growth sector. InMed is one of only a few pure-play cannabinoid biopharmaceutical companies to be trading on one of the world's senior stock exchanges."

In connection with the listing of the Common Shares on the TSX, InMed will make application to the Canadian Stock Exchange ("CSE") to voluntarily delist the Common Shares from the CSE. Such delisting will be effective as of the date the Common Shares commence trading on the TSX.

Shareholders are not required to exchange their stock certificates or take any other action in connection with the TSX listing, as there will be no change in the trading symbol or CUSIP for the Common Shares.

Original source can be found here.